Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Blood (2024) 144 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2024-205959

Published: 2024

Journal Articles

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

Jatinder K. Lamba, Richard J Marrero, Huiyun Wu, Xueyuan Cao, Phani Krishna Parcha, Seth E. Karol, Hiroto Inaba, Dennis John Kuo, Barbara Degar, Kenneth Matthew Heym, Jeffrey Taub, Norman J. Lacayo, Ching-Hon Pui, Raul C. Ribeiro, Stanley Pounds, Jeffrey E. Rubnitz

Blood (2023) 142 (Supplement 1): 386.

https://doi.org/10.1182/blood-2023-173617

Published: 2023

Journal Articles

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Franco Locatelli, MD PhD, Michael B. Jordan, MD, Carl Allen, Simone Cesaro, MD, Carmelo Rizzari, Anupama Rao, Barbara Degar, MD, Tim Garrington, MD, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena Diaz, Michael Henry, MD, Fabrizio De Benedetti, MD, Alexei Grom, Anna Stoltenberg, Mårten Vågerö, Cristina de Min

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-140692

Published: 2020

Journal Articles

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140766

Published: 2020

Journal Articles

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli, Michael B. Jordan, MD, Carl E. Allen, MDPhD, Simone Cesaro, MD, Carmelo Rizzari, MD, Anupama Rao, MD, Barbara Degar, MD, Timothy Garrington, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena, MD, Alexei A. Grom, MD, Fabrizio De Benedetti, MD, Walter Giovanni Ferlin, PhD, Maria Ballabio, MD, Cristina De Min, MD

Blood (2018) 132 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood-2018-120810

Published: 2018

Journal Articles

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Seth E Karol, MD, Elaine Coustan-Smith, MS, Xueyuan Cao, PhD, Sheila A Shurtleff, PhD, Susana C Raimondi, PhD, John K Choi, MD, PhD, Raul C Ribeiro, MD, Gary V Dahl, MD, W Paul Bowman, MD, Jeffrey W Taub, MD, Barbara Degar, MD, Wing Leung, MD, PhD, James R Downing, MD, Ching-Hon Pui, MD, Jeffrey E Rubnitz, MD, PhD, Dario Campana, MD, PhD, Hiroto Inaba, MD, PhD

Blood (2013) 122 (21): 490.

https://doi.org/10.1182/blood.V122.21.490.490

Published: 2013

Journal Articles

Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.

Jeffrey Rubnitz, MD, PhD, Hiroto Inaba, MD, PhD, Gary Dahl, MD, W. Paul Bowman, Jeffrey Taub, MD, Ching-Hon Pui, MD, Stanley Pounds, Norman J. Lacayo, MD, Xueyuan Cao, Raul C. Ribeiro, MD, Soheil Meshinchi, MD, PhD, Barbara Degar, MD, Gladstone Airewele, Mihaela Onciu, MD, Elaine Coustan-Smith, MS, Dario Campana, MD, PhD

Blood (2009) 114 (22): 16.

https://doi.org/10.1182/blood.V114.22.16.16

Published: 2009

NARROW

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.

Email alerts

ASH Publications

American Society of Hematology

Treatment Strategies and Outcomes of the Rare Histiocytic Disorders: Long-Term Results of the International Rare Histiocytic Disorders Registry (IRHDR)

Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes

Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)

Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy

Minimal Residual Disease–Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only